Clinical Trial Update: Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous CAR-T cells targeting Kappa Myeloma Antigen (KMA) in patients with relapsed or refractory multiple myeloma; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Autologous CAR T-cells targeting Kappa Myeloma Antigen (KMA)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING